Document Detail

Annual Trends in Use of Periconceptional Folic Acid and Birth Prevalence of Major Congenital Malformations.
MedLine Citation:
PMID:  23845112     Owner:  NLM     Status:  Publisher    
BACKGROUND: Recent evidence suggests that periconceptional folic acid use could not only prevent neural tube defects but also other malformations. The objectives of this study were to assess trends in dispensed high dose periconceptional folic acid (5 mg) and birth prevalence of major congenital malformations.
METHODS: The Quebec Pregnancy Registry, an administrative database with information on periconceptional prescribed medication and diagnostic codes was used to conduct this study. All pregnant women insured by the Quebec public drug plan between January 1st 1998 and December 31st 2008 were included. The exposure was defined as the use of high dose periconceptional folic acid 30 days before, and during the first 70 days of pregnancy. The outcome measured was the birth prevalence of major congenital malformations among live births.
RESULTS: We identified 152,392 pregnancies and babies. The annual prevalence of high dose periconceptional folic acid use increased from 0.17% to 0.80% (p<0.05) during the study period; birth prevalence of congenital malformations increased by 15% (3.35% to 3.87%, p<0.05). More specifically, a 23% increase in the prevalence of cardiac malformation and 23% increase in musculoskeletal defects were observed, whereas there was no change in the prevalence of malformations of the nervous system.
CONCLUSIONS: Although there was an increase in the use of periconceptional high dose folic acid over the past decade, there was no decrease in the prevalence of major congenital malformations. A limitation of this study is the absence of data on low dose folic acid use, available over the counter, in our administrative database.
Audrey-Ann Richard-Tremblay; Odile Sheehy; Anick Bérard
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-7-08
Journal Detail:
Title:  Current drug safety     Volume:  -     ISSN:  2212-3911     ISO Abbreviation:  Curr Drug Saf     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-7-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101270895     Medline TA:  Curr Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Research Center, CHU Sainte-Justine, 3175, Côte-Sainte-Catherine, Montréal (Quebec) H3T 1C5.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Metronidazole induced DNA damage in somatic cells of Drosophila melanogaster.
Next Document:  Association Between Matrix Metalloproteinase (MMP)-2, MMP-9 and Total Antioxidant Status of Patients...